Delving into the Latest Updates on ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd. with Synapse

Overview

Tags

Nervous System Diseases

Immune System Diseases

Hemic and Lymphatic Diseases

Antibody fusion proteins

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Hemic and Lymphatic Diseases	1
Infectious Diseases	1
Immune System Diseases	1
Nervous System Diseases	1
Neoplasms	1

Top 5 Drug Type	Count

Antibody fusion proteins	1

Top 5 Target	Count

CD20 x CD47	1

Evaluate the safety of different doses of IMC-002 in the treatment of patients with active systemic lupus erythematosus and determine the recommended Phase II dose of IMC-002 Evaluate the effectiveness of IMC-002 compared with placebo in the treatment of patients with active systemic lupus erythematosus.

Start Date-

Sponsor / Collaborator

ImmuneOnco Biopharmaceuticals (Shanghai), Inc.Startup

[+1]

NCT06557174

/ Not yet recruitingPhase 1/2

A Phase Ib/III Multi-center, Randomized and Positive Control Study to Evaluate IMC-002 Safety and Efficacy in in Neuromyelitis Optica Spectrum Disorder (NMOSD) Patients

The purpose of this study is to evaluate the efficacy and safety of IMC-002 in the treatment of NMOSD.

Start Date10 Oct 2024

Sponsor / Collaborator

ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.

NCT06535412

/ Not yet recruitingPhase 1/2

A Multi-center, Randomized, Double-blind, Placebo Control Phase 1b/II Study to Evaluate the Safety and Efficacy of IMC-002 for the Treatment of Active Systemic Lupus Erythematosus

The purpose of this study is to evaluate the efficacy and safety of IMC-002 in the treatment of active SLE.

Start Date10 Oct 2024

Sponsor / Collaborator

ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.

100 Clinical Results associated with ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.

Login to view more data

0 Patents (Medical) associated with ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.

Login to view more data

100 Deals associated with ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.

Login to view more data

100 Translational Medicine associated with ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 12 Feb 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 2 Clinical

1

Login to view more data